C1632 suppresses the migration and proliferation of non‐small‐cell lung cancer cells involving LIN28 and FGFR1 pathway

Chemoresistance and migration represent major obstacles in the therapy of non‐small‐cell lung cancer (NSCLC), which accounts for approximately 85% of lung cancer patients in clinic. In the present study, we report that the compound C1632 is preferentially distributed in the lung after oral administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jing‐yi, Chen, Yu‐jing, Liu, Lu, Jin, Xiang‐xiang, Shen, Zhe, Chen, Wen‐bin, Yang, Teng, Xu, Si‐bei, Wang, Guang‐bao, Cheng, Yi‐nuo, Cheng, De‐zhi, Liu, Zhi‐guo, Zheng, Xiao‐hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743659/
https://www.ncbi.nlm.nih.gov/pubmed/34913237
http://dx.doi.org/10.1111/jcmm.17094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743659/
https://www.ncbi.nlm.nih.gov/pubmed/34913237
http://dx.doi.org/10.1111/jcmm.17094

Ejemplares similares